EIB lends EUR 20m toTransgene

le
0
Today, 28 January 2016, the European Investment Bank (EIB) and Transgene announced that they have entered into a EUR 20m financing agreement. The event organised to mark the granting of this loan will take place at Transgene's headquarters in Illkirch-Graffenstaden, in the presence of Ambroise Fayolle, EIB Vice-President responsible for innovation, Alain Mérieux, Chairman of Institut Mérieux, Transgene's leading shareholder, and Philippe Archinard, Transgene's Chairman and CEO.

This is a key loan, which will help finance Transgene's new clinical developments for the treatment of infectious diseases, including chronic hepatitis B, virus-induced cancers such as HPV (human papilloma virus) and tuberculosis.

European Commissioner for Research, Science and Innovation Carlos Moedas commented: "This deal under InnovFin's IDFF facility, once again shows the EU's determination to tackle major public health problems. We hope that this loan will help to improve the treatment and quality of life of people affected by these diseases."


Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.

Pour consulter le fichier PDF en intégralité, cliquez ici.

Pour visualiser les documents au format PDF, vous pouvez télécharger gratuitement Acrobat Reader XI.


Valeur associée
  Libellé Bourse Dernier Var. Vol.
Vous devez être membre pour ajouter des commentaires.
Devenez membre, ou connectez-vous.
Aucun commentaire n'est disponible pour l'instant